You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Multiple Myeloma

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

New Echocardiographic Indicators in Treatment of Primary

Not yet recruiting
  • Multiple Myeloma
  • Chemotherapy and/or autologous hematopoietic stem cell transplantation
  • (no location specified)
Sep 18, 2023

Multiple Myeloma, Fatigue, Pain Trial (Auricular Acupuncture)

Not yet recruiting
  • Multiple Myeloma
  • +3 more
  • Auricular Acupuncture
  • (no location specified)
Mar 7, 2023

Multiple Myeloma Trial (Patient Reported Outcomes)

Not yet recruiting
  • Multiple Myeloma
  • Patient Reported Outcomes
  • (no location specified)
Apr 24, 2023

Optical Genome Mapping in Characterization of Multiple Myeloma

Not yet recruiting
  • Multiple Myeloma
  • Bone Marrow samples collection
  • Strasbourg, France
    Institut de cancérologie Strasbourg Europe
Mar 15, 2023

Belantamab Mafodotin Care Patterns in Relapsed and/or Refractory

Not yet recruiting
  • Multiple Myeloma
  • Durham, North Carolina
    Duke University Medical Center
Aug 8, 2023

Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma Trial in Wuhan (Daratumumab, Carfilzomib,

Recruiting
  • Multiple Myeloma
  • +2 more
  • Wuhan, Hubei, China
    Institute of Hematology, Union Hospital, Tongji Medical College,
Nov 18, 2023

Relapsed/Refractory Multiple Myeloma Trial in Benowa (ISB 2001)

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • ISB 2001
  • Benowa, Queensland, Australia
    Pindara Private Hospital
May 18, 2023

Guiding the Treatment in Older Newly Diagnosed Multiple Myeloma

Not yet recruiting
  • Multiple Myeloma
  • Frailty
    • (no location specified)
    Oct 30, 2023

    Multiple Myeloma in Remission Trial in Shenzhen, Haikou (MM-specific universal CAR T cells)

    Recruiting
    • Multiple Myeloma in Remission
    • MM-specific universal CAR T cells
    • Shenzhen, Guangdong, China
    • +1 more
    Aug 23, 2023

    Relapsed or Refractory Multiple Myeloma Trial (Forimtamig, Carfilzomib, Daratumumab)

    Not yet recruiting
    • Relapsed or Refractory Multiple Myeloma
    • (no location specified)
    Sep 20, 2023

    Refractory Multiple Myeloma, Relapsed Multiple Myeloma Trial in Miami (Iberdomide, Carfilzomib, Daratumumab)

    Not yet recruiting
    • Refractory Multiple Myeloma
    • Relapsed Multiple Myeloma
    • Miami, Florida
      University of Miami
    May 31, 2023

    Determine the Optimal Initial Therapy for Multiple Myeloma

    Recruiting
    • Multiple Myeloma
    • Non-Interventional Study
    • Scottsdale, Arizona
    • +3 more
    Nov 22, 2023

    Real-World Mapping Antithrombotic Regimens in MM Patients on

    Not yet recruiting
    • Multiple Myeloma
    • Diagnosis
      • (no location specified)
      Aug 31, 2023

      Multiple Myeloma, Relapse Multiple Myeloma Trial in Chicago (Belantamab mafodotin, Carfilzomib, Pomalidomide)

      Not yet recruiting
      • Multiple Myeloma
      • Relapse Multiple Myeloma
      • Belantamab mafodotin
      • +3 more
      • Chicago, Illinois
        University of Chicago Medicine Comprehensive Cancer Center
      Mar 23, 2023

      Multiple Myeloma Trial in Canton (Lenalidomide)

      Recruiting
      • Multiple Myeloma
      • Canton, Ohio
        Gabrail Cancer & Research Center
      Oct 11, 2023

      Multiple Myeloma Trial in Saint Louis (Care transition, No care transition)

      Not yet recruiting
      • Multiple Myeloma
      • Care transition
      • No care transition
      • Saint Louis, Missouri
        Washington University School of Medicine
      Jul 30, 2023

      Relapsed and Refractory Multiple Myeloma Trial in Pittsburgh (Mezigdomide, Ixazomib, Dexamethasone)

      Not yet recruiting
      • Relapsed and Refractory Multiple Myeloma
      • Pittsburgh, Pennsylvania
        UPMC Hillman Cancer Center
      Sep 15, 2023

      Relapse/Refractory Multiple Myeloma Trial in Hangzhou (DeepTag-GPRC5D Targeted CAR T-cells)

      Recruiting
      • Relapse/Refractory Multiple Myeloma
      • DeepTag-GPRC5D Targeted CAR T-cells
      • Hangzhou, Zhejiang, China
        The first affiliated hospital of medical college of zhejiang uni
      Oct 10, 2023

      Health Technology Intervention on Patient Activation in Multiple

      Not yet recruiting
      • Multiple Myeloma in Relapse
      • +3 more
        • (no location specified)
        Jan 9, 2023

        Real-world Usage of HyQvia in Multiple Myeloma Secondary

        Not yet recruiting
        • Multiple Myeloma
        • Secondary Immunodeficiency (SID)
        • No Intervention
        • (no location specified)
        May 19, 2023

        Alvocade® (Bortezomib) Safety and Effectiveness Study

        Completed
        • Multiple Myeloma, Refractory
        • (no location specified)
        Aug 19, 2023

        Multiple Myeloma Trial in Miami (Teclistamab, Talquetamab, Daratumumab SC)

        Not yet recruiting
        • Multiple Myeloma
        • Miami, Florida
          University of Miami
        Oct 20, 2023

        Multiple Myeloma Trial in Xuzhou (APRIL-BAFF-Bicephali CAR-T cells)

        Recruiting
        • Multiple Myeloma
        • APRIL-BAFF-Bicephali CAR-T cells
        • Xuzhou, Jiangsu, China
          Kailin Xu
        Nov 14, 2023

        Multiple Myeloma, Myeloma-Associated Amyloidosis Trial in Saint Louis (Selinexor, Lenalidomide, Dexamethasone)

        Not yet recruiting
        • Multiple Myeloma
        • Myeloma-Associated Amyloidosis
        • Saint Louis, Missouri
          Washington University School of Medicine
        Apr 6, 2023

        Multiple Myeloma, Chronic Lymphocytic Leukemia Trial in Durham (Myeloma Coach or CLL Coach Mobile App, Springboard Beyond Cancer

        Completed
        • Multiple Myeloma
        • Chronic Lymphocytic Leukemia
        • Myeloma Coach or CLL Coach Mobile App
        • Springboard Beyond Cancer informational website
        • Durham, North Carolina
          Duke University
        Jun 23, 2023